Pharma Stocks Outlook
Seen stuck in range; India-US deal may give push
This story was originally published at 21:32 IST on 27 June 2025
Register to read our real-time news.Informist, Friday, Jun. 27, 2025
MUMBAI – The Nifty Pharma index is expected to remain range-bound next week, moving between 21200 and 22000 points, technical analysts said. The index ended 0.6% higher Friday at 21928.60 points, rising 1.5% from the previous week. Strong valuations and a likely India-US trade deal would lay down a smooth path for the index for the long run, research analysts said.
Finance Minister Nirmala Sitharaman had said Tuesday that the government is looking forward to signing an interim deal with the US, which would later become part of the first tranche of their trade agreement, by Jul. 9. Washington had paused its reciprocal tariffs till Jul. 8, and if they kick in once again, India's exports to the US will become 26% more expensive. India and the European Union will hold the next round of negotiations for a free trade agreement from Jul. 7.
However, media reports said trade discussions between India and the US have come to a halt after disagreements on import duties for automotive components, steel, and farm goods, Reuters reported citing Indian officials with direct knowledge of the matter.
A fresh headwind for the Indian pharmaceutical sector is the health ministry's discussions with states, pressing them to cancel the licence of drug companies found guilty of not maintaining quality standards. According to a report in The Economic Times, the Central Drug Standards Control Organisation has been deliberating on the matter with pharmaceutical lobby groups, which have raised objections.
Global brokerage Jefferies recently said it is bullish on the Indian pharmaceutical sector as big foreign companies are diversifying geographically, which would benefit Indian contract research, development, and manufacturing companies with specific expertise.
Friday, Abbott India was the best performing constituent of the Nifty Pharma, closing nearly 6% higher. Torrent Pharmaceuticals and Laurus Labs ended over 3% higher each. Among the worst-hit in the index, Ajanta Pharma and Dr. Reddy's Laboratories closed nearly 2% down. Glenmark Pharmaceuticals snapped a two-day winning streak and declined over 1%.
TOP HEADLINES
* Biocon to buy 1,125 optionally conv debs of Biocon Biologics for $198.50 mln
* Lupin launches prucalopride tablets in US
* Laurus Labs invests INR 399.99 mln in subsidiary Laurus Bio
* US FDA audits in India near pre-COVID levels; compliance improves: CareEdge
* IPO Alert: Sudeep Pharma files draft papers with SEBI for fresh issue, OFS
* Lupin gets US FDA approval for generic Prucalopride tablets
* JB Chem gets US FDA approval for Amitriptyline Hydrochloride tablets
* Aurobindo Pharma arm gets nod from UK drug body to market biosimilar Dyrupeg
* Concord Biotech gets establishment inspection report for facility at Dholka
* IPO Alert: Amanta Healthcare gets SEBI nod for fresh issue of 12.5 mln shrs
* Gland Pharma gets US FDA establishment inspection report for Vizag unit
* Biocon arm to launch assistance program for cancer patients in Malaysia
* Glenmark Pharma launches cancer drug Tevimbra in India
* Alkem Laboratories completes Madhya Pradesh unit sale to Rubicon Research
* NCLT admits NARCL's insolvency plea against former CEO of Parenteral Drugs
* Emcure Pharma board OKs purchase of 4.1 mln shrs of arm for INR 7.25 bln
* TPG Asia sells 10% shrs in Sai Life in block deal; Nippon India MF buys 2.4%
* Biocon concludes INR-45-bln QIP; to use funds to buy conv debs issued by arm
* US FDA issues one observation to Granules India's API unit in Hyderabad
Following are the resistance and support levels for the stocks for next week, as per calculations based on their prices on the National Stock Exchange:
| Company | Price | Week-on-Week Change in % | Resistance | Support |
| Abbott India | 34,940.00 | 10.50 | 39,010.00 | 30,920.00 |
| Alkem Laboratories | 4,906.50 | 2.80 | 4,958.80 | 4,828.80 |
| Aurobindo Pharma | 1,121.00 | 2.20 | 1,146.10 | 1,106.50 |
| Biocon | 354.40 | 0.90 | 358.90 | 347.80 |
| Cipla | 1,502.40 | 0.20 | 1,517.70 | 1,484.30 |
| Divis Laboratories | 6,658.00 | 1.00 | 6,777.30 | 6,491.30 |
| Dr. Reddy's Laboratories | 1,301.00 | (-)1.80 | 1,343.50 | 1,277.10 |
| Gland Pharma | 1,781.40 | 3.40 | 1,812.20 | 1,760.60 |
| GlaxoSmithKline Pharmaceuticals | 3,439.60 | 7.00 | 3,618.00 | 3,203.60 |
| Glenmark Pharmaceuticals | 1,711.20 | 4.60 | 1,749.90 | 1,687.50 |
| Granules India | 497.20 | 2.00 | 506.60 | 490.30 |
| Ipca Laboratories | 1,331.70 | (-)1.70 | 1,391.40 | 1,294.20 |
| Laurus Labs | 701.80 | 7.80 | 720.50 | 669.30 |
| Lupin | 1,935.20 | (-)0.70 | 1,966.10 | 1,908.70 |
| Natco Pharma | 884.45 | 1.10 | 925.40 | 845.50 |
| Pfizer | 5,698.00 | 2.00 | 5,815.30 | 5,577.30 |
| Sanofi India | 6,192.00 | 3.10 | 6,247.30 | 6,105.30 |
| Sun Pharmaceutical Industries | 1,687.60 | 1.40 | 1,711.30 | 1,656.30 |
| Torrent Pharmaceuticals | 3,341.40 | 5.50 | 3,425.10 | 3,245.10 |
| Zydus Lifesciences | 981.80 | 2.60 | 993.10 | 973.50 |
| Nifty Pharma | 21928.60 | 1.50 | 22095.10 | 21740.30 |
| Nifty 50 | 25637.80 | 2.10 | 25735.80 | 25474.50 |
| S&P Bse Sensex | 84058.90 | 2.00 | 84375.20 | 83487.30 |
End
Reported by P. Madhu Kumar
Edited by Rajeev Pai
For users of real-time market data terminals, Informist news is available exclusively on the NSE Cogencis WorkStation.
Cogencis news is now Informist news. This follows the acquisition of Cogencis Information Services Ltd by NSE Data & Analytics Ltd, a 100% subsidiary of the National Stock Exchange of India Ltd. As a part of the transaction, the news department of Cogencis has been sold to Informist Media Pvt Ltd.
Informist Media Tel +91 (22) 6985-4000
Send comments to feedback@informistmedia.com
© Informist Media Pvt. Ltd. 2025. All rights reserved.
To read more please subscribe
Share this Story:
